Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O75161

UPID:
NPHP4_HUMAN

ALTERNATIVE NAMES:
Nephroretinin

ALTERNATIVE UPACC:
O75161; Q8IWC0

BACKGROUND:
The protein Nephrocystin-4, alternatively named Nephroretinin, is instrumental in cilia function and cellular signaling. It facilitates the organization of apical junctions, interacts with INT and DAAM1 for actin network organization, and plays a role in several key pathways, including Wnt-PCP and the hippo pathway, by stabilizing JADE1 and interacting with LATS1.

THERAPEUTIC SIGNIFICANCE:
Linked to the development of Nephronophthisis 4 and Senior-Loken syndrome 4, Nephrocystin-4's involvement in these genetic disorders highlights its potential as a target for therapeutic intervention. The exploration of Nephrocystin-4's functions and mechanisms offers promising avenues for the treatment of these renal and renal-retinal diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.